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Abstract             
Introduction: Major depressive disorder is a common mental condition associated with 
substantial morbidity and economic burden. Approved by the FDA in September 2013 for 
treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options 
available in this important area of therapeutics. 
Materials and methods: A comprehensive literature search (PubMed, the Cochrane library, 
Scopus, CRD and HTA Database in January 2015) was performed, containing controlled 
clinical trials that vortioxetine 10 mg/d versus placebo in adults with major depressive 
disorder. 
Results: Six controlled clinical trials were included in this meta-analysis. There was a 
significant difference between the vortioxetine 10 mg/d versus placebo in the Montgomery–
Åsberg Depression Rating Scale (MADRS) (P value <0.00001). The results of pooled 
analysis for diarrhea, dry mouth, dizziness, headache and nausea were also significant (P 
value <0.00001). Vortioxetine 10 mg/d versus placebo showed a significant difference for 
nausea, but no significant differences were observed for the other five adverse effects. 
Conclusion: Therapy with vortioxetine was significantly associated with reduction in 
depression symptoms from baseline compared to placebo. 
Keywords: Vortioxetine 10 mg/d, Systematic Review, Meta-analysis, Major Depressive 
Disorder 
Introduction 
Major depressive disorder (MDD) is 
characterized essentially by ‘‘depressed 
mood’’ and ‘‘loss of interest or pleasure in 
nearly all activities’’ according to the 
Diagnostic and Statistical Manual of 
Mental Disorders IV (1). Major depressive 
disorder is a common mental condition 
associated with substantial morbidity and 
economic burden. The World Health 
Organization ranks depression as the 
largest contributor to years lost to 
disability and the fourth largest contributor 
to disability-adjusted life-years (2). Signs 
and symptoms include feelings of guilt, 
anxiety, fatigue, sleep dis- turbans, and 
cognitive and sexual dysfunction 
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(3).Depression is a serious, common, and a 
recurring disorder linked to diminished 
functioning, quality of life, medical 
morbidity, and mortality (4). There has 
been a 37.5% increase in health, life years 
lost to depression over the past two 
decades (5). Depression was the third-
leading cause of the global burden of 
disease in 2004 and the leading cause of 
burden of disease in high- and middle-
income countries. It is projected to be the 
leading cause globally in 2030 (6). While 
effective treatments for depression are 
available, they are used. Barriers to 
treatment include geography, 
socioeconomic status, system capacity, 
treatment costs (direct and indirect), low 
mental health literacy, cultural beliefs, and 
stigma (7, 8). A 2010 study found that 
75% of primary care patients with 
depression in urban areas could identify 
more than one structural, psychological, 
cultural, or emotional barrier to accessing 
behavioral treatments. The rate was 
substantially higher in rural areas (9). 
Vortioxetine is one of the newer options 
available in this important area of 
therapeutics ,that approved by the FDA in 
September 2013 for treatment of episodes 
of major depressive disorder (10).More 
than 30 pharmacotherapy options are 
available for unipolar depression, 
including: selective serotonin reuptake 
inhibitors (SSRIs), tricyclic 
antidepressants (TCAs), serotonin-
norepinephrine reuptake inhibitors 
(SNRIs), bupropion, serotonin 
antagonist/reuptake inhibitors, second-
generation antipsychotics, alpha2 
antagonists, monoamine oxidase inhibitors 
(MAOIs), norepinephrine reuptake 
inhibitors, and tetracyclics. These 
treatments are meant to reduce mortality 
and improve quality of life (11). 
After oral administration, Vortioxetine is 
absorbed in the gastrointestinal tract and 
exhibits peak plasma concentrations in 
about seven to 11 hours (Tmax). Its bio-
availability is 75%. Consumption of food 
does not affect the bioavailability, and 
taking vortioxetine with food has not been 
shown to increase its peak concentration 
(Cmax) (12).The efficacy of vortioxetine 
was demonstrated in 6 positive 6 to 8week 
randomized, double-blind, placebo-
controlled studies, including one study 
conducted in elderly patients and one 
maintenance study. These studies 
demonstrated statistically significant 
improvements in overall symptoms of 
depression in adults with MDD based in 
Montgomery-Asberg Depression Rating 
Scale (MADRS). (12). The objective of 
this Meta – analysis was to evaluate the 
efficacy and safety of vortioxetine 10 mg/d 
versus placebo in adults with Major 
depressive disorder. 
Materials and Methods  
Search strategy: Electronic searches were 
performed in the Cochrane library, 
PubMed, Scopus, CRD and HTA Database 
in January 2015. We also searched 
ClinicalTrials.gov because it includes the 
results of both publicly and privately 
supported clinical studies of humans 
participants conducted worldwide. Our 
searches will not be limited by language, 
publication status or setting. The reference 
lists of articles and other reviews retrieved 
in the search or known to the authors will 
be searched for relevant articles. 
Unpublished work will be identified by 
searching the abstract books or websites of 
two major conferences: the International 
depressive disorder Conference, the 
Anxiety Disorders and Depression 
Conference. An abstract of interest will be 
assessed in further detail by contacting the 
authors. We will try to contact the authors 
of included studies to acquire other data 
that may either be unpublished or 
informally published or ongoing and 
which is related to efficacy of vortioxetine 
in depression. Data collection and analysis 
a summary of the identification, screening 
and inclusion of studies in this review will 
be presented as a PRISMA (13) (Figure 1).




Figure 1. Flow diagram for article selection. 
 
Two review authors (Masoud. B, Meysam. 
B) Will independently screen and select 
studies for possible inclusion in the study. 
First, the titles and abstracts of trials 
identified from the search will be 
independently reviewed and pooled for 
further screening. Secondly, each review 
author will independently examine the full 
text of all trials that were identified from 
the title and abstract scenes. Each reviewer 
will compile a list of studies that meet the 
inclusion criteria. The contents of each 
review author’s list will be compared, and 
any disagreement will be resolved by 
discussion and consensus between all of 
the review authors. 
Inclusion criteria: Clinical trials testing 
the efficacy of vortioxetine for the Major 
depressive disorder were eligible for 
inclusion. Included studies had to be RCTs 
comparing vortioxetine with placebo. We 
considered trials that recruited patients for 
evaluation of other outcomes if they also 
met the aforementioned criteria for Major 
depressive disorder and included data for 
outcomes of major depressive disorder. 
Studies were excluded if the main outcome 
were prevention of relapse or if treatment 
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outcomes based on rating scales of MDD 
were not available.  
Data extraction: We collected data on 
participant characteristics, treatment de-
tails, study procedures, efficacy measures 
and Adverse Events (AEs). These data 
included, for example, group (treatment, 
placebo), size sample, age, sex, duration of 
treatment, baseline MADRS, doses and 
study location. A summary of the 
characteristics of the included studies is 
presented in Table 1. Outcome data related 
to the characteristics of the individual trial 
and the reported results were extracted for 
each trial. The efficacy measures were the 
mean change from baseline in total scores 
on the MADRS. The MADRS is a ten-
item diagnostic questionnaire which 
psychiatrists use to measure the severity of 
depressive episodes in patients with mood 
disorders (14). If studies compared 
different doses of vortioxetine to the 
placebo, we only included data comparing 
the 10 mg/day and placebo doses. For 
assessed of safety of vortioxetin 10 mg, 
Data on the number of dropouts (for any 
reason), lack of efficacy and incidence of 
AEs were included in the analysis (Table 
1).
  
Table 1. Summary of the included studies in the Meta-analysis. 
Author 
 
Group Cases Age (year) 
 
M/F Baseline MADRS 
score 
Doses  Study location Entry score by 
MADRS 
Alvarez T 100 42.3 ±13.1   34:66 34.0±2.8 5,10 Europe/Asia ≥30 
P 105 42.0 ±10.9 36:69 33.9±2.7 
Baldwin T 151 45.2 ±13.1 51:100 30.4±5.4 2.5,5,10 Europe/Asia ≥26 
P 148 43.4 ±12.5 45:103 29.8±5.1 
Henigsberg T 140 46.4 ±12.27   55:85 33.1±4.8 1,5,10 Europe/Asia/Africa ≥26 
P 140 46.4 ±12.26   54:86 32.7±4.4 
Jacobsen T 155 43.1 ±12.04 37:118 32.3±4.5 10,20 USA ≥26 
P 157   42.3 ±11.61 47:110 32.0±4.0 
Mahableshwarkar T 157   45.2 ±11.94 44:113 34.1±4.1 10,15 USA ≥26 





T 150 45.7 ±10.90   57:93 31.8±4.0 5,10,20 Europe/Asia ≥26 
P 152 43.6 ±11.57 61:91 31.6±3.6 
 
T, treatment; P, placebo; M, male; F, female.  
 
Assessment of risk of bias in included 
studies: Quality of studies was rated 
according to the Cochrane Collaboration’s 
Tool for Assessing Risk of Bias (15), 
including Random sequence generation 
(selection bias), Allocation concealment 
(selection bias), Blinding of participants 
and personnel (performance bias), 
Blinding of outcome assessment (detection 
bias), incomplete outcome data (attrition 
bias), Selective reporting (reporting bias) 
and other bias (Figure 2). 
 




Figure 2. Assessment of risk of bias in included studies according to the Cochrane Collaboration’s Tool. 
 
Quality assessment of the included 
studies: The Jadad score is an instrument 
used to assess the quality of randomized 
clinical trials (RCTs). It includes three 
items as follows: randomization (The 
study was not randomized or an 
inappropriate method of randomization 
was used, the study was described as 
Randomized, the method of randomization 
was described and it was appropriate), 
blindness (The study was not blind or an 
Inappropriate method of blinding was 
used, The study was described as double 
blind, the method of double blinding was 
described and it was appropriate), and 
dropouts (The dropouts were not described 
in the follow-up, The study contained a 
description of withdrawals and dropouts). 
The score standards and the results of our 
included studies are shown in Table 2, 
respectively. We are rated as providing 
good methodological quality based on a 
Jadad score of 1-5. So the total scores for 
all included articles indicated a high study 
quality. The study quality was assessed 
with Jadad scores (16). 
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Table 2. Jaded score quality assessment of the included studies. 
Name study Years study Randomization Blindness Dropouts Jaded scores 
Alvarez 2012 2 2 1 5 
Baldwin 2012 2 2 1 5 
Henigsberg 2012 2 2 1 5 
Jacobsen 2013 2 2 1 5 
Mahableshwarkar 2013 2 2 1 5 
Trial NCT01255787 2014 2 2 1 5 
Statistical analysis 
In the review, we assessed MADRS and 
adverse effects randomized into the 
vortioxetine 10 mg/day and placebo 
groups for each trial were statistically 
combined using by Mantel–Haenszel 
random effects model. The effects were 
expressed as standard means different 
ratios (SMD) with 95% confidence 
intervals (CIs) and p values. The incidence 
of adverse effects between the vortioxetine 
10 mg/day and placebo groups was also 
determined using the Mantel–Haenszel 
model, and the results were expressed as 
the Odds Ratio (ORs) with the 95 % CI 
and p values. The heterogeneity across 
each effect size was evaluated by using the 
I2 and Chi-squared tests statistic. This 
measure evaluates how much of the 
variance among studies can be attributed 
to the actual differences among the studies 
rather than to chance. A magnitude of 
considerable heterogeneity is usually I2 = 
75%–100 %( 17). A sensitivity analysis 
was performed to rule out the possibility 
that any single study strongly influenced 
the pooled effect. Publication bias was 
assessed by a funnel plot, Egger’s test 
(18), and Begg’s rank correlation test (19). 
Statistical analyses were conducted using 
Rev Man 5.3 software from the Cochrane 
Collaboration and Stata 12 software. 
Results 
Efficacy: Overall, 6 articles met the 
inclusion criteria and were finally used for 
this meta-analysis. This article consists 
Alvarez et al (20), Baldwin et al (21), 
Henigsberg et al (22), Jacobsen et al(23), 
Mahableshwarkar et al (24) and trial no 
NCT01255787(25). A total of six studies 
with 1715 patients, 853 in the 10 mg/day 
Vortioxetine group and 862 patients in the 
placebo group. The SMD for MADRS 
with vortioxetine 10 mg compared to 
placebo was -3.22 with 95% CI [-4.55, -
1.89] and P value <0.00001 and 
heterogeneity for the MADRS scale was 
I2= 99 % (Figure 3). 
 
 
Figure 3. Forest plot of Standard Different Mean ratios (SMD), 95 % confidence intervals (CIs in the 
Montgomery–Åsberg Depression Rating Scale (MADRS). 
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Safety: Drug safety evaluation for 
symptoms that have been observed in 
studies was meta-analysis. The most 
common side effects were diarrhea, dry 
mouth, dizziness, fatigue, headache and 
nausea. Results the 10 mg/day vortioxetine 
compared to placebo showed for diarrhea 
OR = 0.84 with 95% CI [0.56, 1.27], P 
value = 0.42 ,for dry mouth result showed 
OR = 0.76 with 95% CI [0.49, 1.9], P 
value = 0.23 , for dizziness OR = 1.02 with 
95% CI [0.57, 1.83], P value = 0.95.for 
fatigue OR = 1.01 with 95% CI [0.59, 
1.73], P value = 0.97 ,for headache OR = 
0.92 with 95% CI [0.70, 1.22], P value = 
0.57 and for nausea OR = 3.89 with 95% 
CI [2.88, 5.26], P value <0.00001.  
Analysis for publication bias: Analysis 
for publication bias in the included studies 
showed, no publication bias was observed 
for the MADRS (Egger’s test: P= 0.003 
respectively, and Begg’s test: P= 0.015 
respectively) and funnel plots, no 
publication bias was observed for Adverse 
Events contain diarrhea, dry mouth, 
Dizziness, fatigue, headache and nausea 
analysis  in the included studies. (Egger’s 
test: P= 0.229, P= 0.162, P=0.373, P= 
0.147, P= 0.488, P= 0.488 respectively and 
Begg’s test: P= 0.188, P= 0.091, P= 0.188, 
P= 0.188, P= 0.573, P= 0.188, 
respectively. 
Sensitivity analysis: A sensitivity analysis 
not found that the pooled remission rate 
was significantly influenced when we 
excluded the study from trial Baldwin et al 
(21). 
Discussion 
The development of vortioxetine, an 
antidepressant with a novel mechanism of 
action, which was approved by the FDA in 
September 2013 for the treatment of major 
depressive disorder (26).In this meta-
analysis, we aimed to evaluate the efficacy 
and safety of vortioxetine at dose 10 mg in 
the treatment of MDD by including 
randomized controlled trials. studies by 
Katona et al (27), Mahableshwarkar et al 
(28-29), Jain et al (30) and  Boulenger et 
al(31) showed that vortioxetine efficacy 
for treatment Major depressive disorder 
(MDD). Improved symptoms in patient of 
major depressive disorder obtained in 
these studies. The present study supports 
the efficacy and safety of using 
vortioxetine 10 mg/d in the treatment 
Major depressive disorder. We identified 
six RCTs (1715 patients) for vortioxetine 
10 mg/d compared placebo. Five study 
(Baldwin, Henigsberg, Jacobsen, 
Mahableshwarkar and Trial 
NCT01255787) during 8 weeks and a 
study (Alvarez) has been done during six-
week. However, these findings must be 
interpreted with caution the quality of 
assessment. The Jadad score is an 
instrument used to assess the quality of 
randomized clinical trials was all 5 studies. 
All the studies according to the 
specifications (Randomization, Blindness 
and Dropouts) of the appropriate quality 
were Jadad. 
The quality of the evidence of the six 
included randomized clinical trial studies, 
six trials clearly described random 
sequence generation. In five trials, 
described blinding of participants and 
personnel and one study unclear risk of 
this bias. In five trials blinding of outcome 
assessment and one study unclear risk of 
this bias, in one study were described 
incomplete outcome data and five studies 
had Selective reporting and five studies 
unclear risks of this bias. 
No statistical evidence was found for 
publication bias or heterogeneity, and the 
results remained significant after any one 
of the trials was removed. The result meta-
analysis of SMD suggest that significant 
differences for MADRS with vortioxetine 
10 mg compared to placebo (SMD = -3.22 
with 95% CI [-4.55, -1.89] and P value 
<0.00001).The decrease in depression 
symptoms seems too associated with 10 
mg/d of vortioxetine versus placebo. 
Clinical trials testing the efficacy of 
vortioxetine for the short-term treatment 
(6-8 weeks.) of major depressive disorder 
were eligible for inclusion. Results of 
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Adverse events (AEs) showed a significant 
for nausea OR = 3.89 with 95% CI [2.88, 
5.26], P value <0.00001, but no significant 
differences were observed for the other 
five adverse effects. AEs discontinuation 
rates were generally low. It suggested that 
the negative results in previous double-
blind, random-controlled studies may have 
been due to an inadequate sample size, 
which can be overcome by the meta-
analytic method. These findings indicate 
that compared to placebo, 20 mg/d mg/day 
vortioxetine significantly improved 
depressive symptoms in patients with 
major depressive disorder. In the 
randomized clinical analyzed, the common 
adverse effects of vortioxetine include 
diarrhea, dizziness, dry mouth, nausea, 
headache and fatigue. The limitations of 
this meta-analysis include the following: 
The inclusion of patients only during the 
acute phase, which did not enable us to 
analyze the long-term efficacy and safety 
of vortioxetine in treating major depressive 
disorder. The included studies did not 
include data on the onset time of 
vortioxetine’s efficacy, and thus, we did 
not compare the onset time between 10 
mg/d vortioxetine and placebo. All 
included trials were supported by the 
Takeda pharmaceutical company, Ltd, as 
part of a joint clinical development 
program with H. Lund beck A/S, which 
may have influenced the results. All 
included studies did not include the 
efficacy and adverse effects based on sex; 
thus, we could not evaluate gender 
differences. Due to the limited number of 
the published articles, we did not analyze 
the efficacy and safety of different doses 
of vortioxetine in the treatment of major 
depressive disorder. The small number of 
included studies and the relatively small 
sample size, which may influence the 
reliability of the results. Treatment of 
depression still remains a challenge, with 
one of the issues being the diversity of the 
individual patient symptom profiles, and 
often residual symptoms persist at the end 
of antidepressant treatment (32).However, 
depression is frequently associated with 
coronary heart diseases (33), diabetes 
mellitus (34), stroke (35), pregnancy, and 
the postpartum period (36). Thus, the use 
of vortioxetine should also benefit the 
physical state of       these patients. Due to 
the small number of trials in our meta-
analysis, our results warrant additional 
studies to verify these findings. In the 
future, additional large-scale and well-
designed Studies are needed to determine 
the optimal dose, the most appropriate 
treatment group, and the efficacy and 
safety of vortioxetine combined with other 
antidepressants in treating depression (37-
38). 
Conclusion 
We found that the vortioxetine 10 mg/d 
may be effective compared with a placebo 
for treatment major depressive disorder. 
The evidence base reported in this review 
is of very good quality and includes only a 
small number of studies, which imposes 
significant limitations for conclusions on 
both efficacy and potential adverse 
outcomes. However, our results should be 
interpreted and translated into clinical 
practice with caution, effect sizes of the 
clinical trials included in the present the 
meta-analysis. Adequately powered, well-
designed, direct-comparison clinical trials 
should also be more clearly addressed the 
comparative efficacy of vortioxetine and 
different antidepressants. The current 
meta-analysis of published RCTs has shed 
light on the benefits of 10 mg/d 
vortioxetine for the treatment of major 
depression disorder. Further studies in the 
future with more ensure that can find this 
drug in the treatment of depressive patients 
rated effectiveness. 
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